INDICATIONS AND USAGE
OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is
indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
IMPORTANT SAFETY INFORMATION
Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported
ocular adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation, increased intraocular pressure,
and anterior chamber infl ammation. OMIDRIA must be added to irrigation solution
prior to use. Use of OMIDRIA in children has not been established.
Please see the Full Prescribing Information for
OMIDRIA at www.omidria.com/prescribinginformation.
IS THE TIME TO PREVENT INTRAOPERATIVE MIOSIS
AND REDUCE POSTOPERATIVE OCULAR PAIN
Omeros
®
and the Omeros logo
®
are registered trademarks, and Omidria
™
and the Omidria logo
™
are trademarks, of Omeros Corporation. © Omeros Corporation 2015, all rights reserved. 2015-070
FDA APPROVED
Visit Booth 417 to learn more
OMIDRIA
™
(phenylephrine and ketorolac injection) 1% / 0.3% In-Booth Speaker Schedule
DATE TIME SPEAKER TOPIC
Saturday, April 18th 2:00–2:30
PM
4:00–4:30
PM
Kevin Corcoran, COE, CPC, CPMA, FNAO
Allison Shuren, MSN, JD
OMIDRIA Reimbursement Discussion
OMIDRIA Reimbursement Discussion
Sunday, April 19th 9:30–10:00
AM
2:00–3:00
PM
4:00–4:30 PM
Kevin Corcoran, COE, CPC, CPMA, FNAO
Stephen Lane, M.D.
Allison Shuren, MSN, JD
OMIDRIA Reimbursement Discussion
OMIDRIA Clinical Discussion
OMIDRIA Reimbursement Discussion
Monday, April 20th 9:00–9:30
AM
2:00–3:00 PM
Eric Donnenfeld, M.D.
Steven Silverstein, M.D.
OMIDRIA Clinical Discussion
OMIDRIA Clinical Discussion
